Quantive Advises BioPharma on Sale
Quantive is pleased to announce that we recently advised Biopharma Global (Biopharma) on its sale to Pace® Life Sciences, LLC.
Minneapolis-based Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and a subsidiary of Pace®, a science and technology company, announced earlier this month that it has acquired Biopharma Global (Biopharma). Biopharma specializes in full-service regulatory support for orphan products to treat rare diseases and non-orphan products to treat indications with unmet medical needs.
“Pace® provides great value in our marketplace through our technical expertise and by meeting the strong commitments we make to our clients that rely on us to successfully advance their programs through development,” said Eric Roman, CEO of Pace®. “The acquisition of Biopharma Global extends our reach further into regulatory strategy, guidance, and support in key therapeutic areas and greatly extends the reach of Pace® into our markets.”
“The Biopharma Global team brings strong expertise in early drug development with sound regulatory strategy guidance and robust submission support,” notes Greg Kupp, President of Pace® Life Sciences. “These services greatly enhance the continuity of offerings we provide to our clients and helps them to efficiently drive new drug candidates through the development process.”
In the coming months, Biopharma will transition to the Pace® brand. The Biopharma operation is located in Vienna, Virginia, and joins Pace® Life Sciences locations near Boston, MA, Salem, NH, Philadelphia, PA, Ann Arbor, MI, San Diego, CA, St. Paul, MN, and San Germán, PR.
Pace® is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.
BioPharma Global is a mission-driven corporation dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutics areas to help drug developers advance treatments for the disease communities with high unmet medical needs. We have assembled a team of globally-recognized experts in the rare diseases and other under-served disease areas, including former FDA staff, and a variety of scientists who have many successful orphan drug designations and other expedited program submissions to their credit. We maintain a completely customer-centric, transparent process through the entirety of our projects.
About Pace® Life Sciences
Pace® Life Sciences provides a full suite of contract CMC development, CTM manufacturing, regulatory compliance, consulting, and facility support services to the pharmaceutical, biopharmaceutical, and gene therapy industries from our network of CDMO sites, GMP analytical testing laboratories, and manufacturing support service centers. Our experienced, highly trained industry experts, and our investment in state-of-the-art development and manufacturing facilities emphasize our commitment to efficiently advancing client programs through the clinic to commercialization. We are dedicated to delivering the best and most reliable services with positive customer experiences across all channels of our business. Part of the Pace® Science and Technology Company, Pace® Life Sciences operates a network of multiple CDMO sites, FDA-registered GMP analytical testing laboratories, and regulatory and manufacturing support service centers across the United States. Media Source: Pam Bednar | firstname.lastname@example.org
Quantive is a veteran-owned and operated financial services firm. We work in three areas:
● Valuation Services — Full-service valuation practice providing transaction, litigation, underwriting, and tax support to both business owners and advisors.
● Value Growth Advisory — We help companies grow and entrepreneurs meet their retirement goals either through Fractional CFO or Certified Exit Planning support.
● M&A Advisory — We help clients successfully exit their companies.
Get in touch — we’d be delighted to discuss how we might be a fit for your particular project.